Amgen Thousand Oaks - Search News

Amgen rebounds

Amgen rebounds after denying bone safety concerns linked to obesity drug

Amgen (NASDAQ:AMGN) shares spiked in the premarket on Wednesday after the company ruled out concerns over loss of bone mineral density linked to its obesity candidate MariTide, which led to a ~7% decline in its share price in the previous session.

MarketWatch · 1d

Amgen Says No Link Between MariTide, Bone Density Loss

Amgen on Wednesday sought to allay concerns that its MariTide ... any bone safety concern or change our conviction in the promise of MariTide," the Thousand Oaks, Calif., biotechnology company said, adding that it looks forward to sharing topline data ...

Reuters on MSN · 1d

Amgen dismisses bone density concerns related to its weight-loss drug

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after those concerns wiped off more than $12 billion from the company's market value.

Barchart on MSN17h

Is Wall Street Bullish or Bearish on Amgen Stock?

Amgen Inc. (AMGN), headquartered in Thousand Oaks, California, discovers, develops, manufactures, and delivers human ...

AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA

Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data.

WTOP News15d

Amgen: Q3 Earnings Snapshot

THOUSAND OAKS, Calif. (AP) — THOUSAND OAKS, Calif. (AP) — Amgen Inc. (AMGN) on Wednesday reported third-quarter net income of $2.83 billion. On a per-share basis, the Thousand Oaks ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Amgen rebounds

Trending now

Related topics